Embolism News and Research

RSS

Hospital mortality rates decline by 7.98% from 2007 to 2009

A new independent study by HealthGrades of patient outcomes at America's hospitals found that patients at 5-star rated hospitals had a 72% lower risk of dying when compared with patients at 1-star-rated hospitals -- an enormous gap that has held steady over the past years even as overall mortality rates have improved.

20 Oct 2010

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

The U.S. Food and Drug Administration (FDA) has approved Pradaxa (dabigatran etexilate) capsules to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AFib).

20 Oct 2010

Covidien to showcase innovative surgical products at 96th ACS Clinical Congress

Covidien, a leading global provider of healthcare products, will preview new devices and showcase some of the Company's most innovative products at the 96th Annual Clinical Congress of the American College of Surgeons.

5 Oct 2010

Breast cancer incidence drops, linked to decline in HRT use

A new Canadian study shows that a significant drop in breast cancer incidence among post-menopausal women from 2002 to 2004 coincided with a sharp drop in hormone replacement therapy (HRT) use during the same period. This is the first study to show the link between HRT use and breast cancer among Canadian women.

24 Sep 2010

Antipsychotics slightly raise risk for blood clots

Antipsychotics or medications that are used to treat psychiatric illnesses such as schizophrenia and bipolar disorder are reported to raise the risk of dangerous blood clots.

23 Sep 2010

Study identifies venous thromboembolism risk factors after THR surgery

Risk factors for venous thromboembolism after total hip replacement (THR) surgery were identified in a new study published in the September 2010 issue of The Journal of Bone and Joint Surgery (JBJS). While the rate of thromboembolism has been significantly reduced through medication, understanding the risk factors could further reduce the likelihood of patients developing this potentially fatal complication.

17 Sep 2010

NBCA arms healthcare professionals to 'Stop the Clot'

The National Blood Clot Alliance (NBCA) is making available an easily accessible, no-cost online curriculum for nurses, nurse practitioners, physician assistants, and pharmacists to help increase understanding about the diagnosis and treatment of blood clots and blood clotting disorders.

15 Sep 2010

Teleflex partners with Access Scientific to distribute The PICC WAND vascular access device

Teleflex has partnered with Access Scientific Incorporated, San Diego, California to become the U.S. distributor of The PICC WAND™ Safety Introducer with ARROW® peelable sheath. This new, all- in-one vascular access device provides clinicians a faster, safer, simpler way to insert a peel away sheath for PICC or Midline catheter placements.

7 Sep 2010

Researchers find link between surgery duration with deep venous thrombosis risk

One of the most severe complications of brain surgery is a life-threatening blood clot in the lungs called a pulmonary embolism.But a Loyola University Health System study published in the Journal of Neurosurgery suggests that screening methods hospitals typically use to access the risk of pulmonary embolisms may fall short.

3 Sep 2010

XARELTO achieves net clinical benefit in treatment of patients with DVT

Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.

2 Sep 2010

ESC issues revised practice guidelines for management of AF

The European Society of Cardiology today issued revised practice guidelines for the management of atrial fibrillation, including guidance on the role of a novel oral treatment, dabigatran etexilate, for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

31 Aug 2010

Phase 3 AVERROES trial reveals apixaban effective for atrial fibrillation patients unsuitable for warfarin

The phase 3 AVERROES (Apixaban Versus Acetylsalicylic acid (ASA) to Prevent Strokes) trial, designed to show the superiority of apixaban over aspirin for the prevention of stroke or systemic embolism in high-risk atrial fibrillation patients unsuitable for treatment with a vitamin K antagonist (warfarin), was terminated early following a recommendation from the Data Monitoring Committee.

31 Aug 2010

Data monitoring committee recommends early termination following impressive results of AVERROES study

The data monitoring committee of the AVERROES study, seeing overwhelming evidence of the success of apixaban in the prevention of stroke in patients with atrial fibrillation who are unsuitable for the conventional treatment of warfarin, has recommended early termination of this study. The decision came after repeated review and careful consideration of all efficacy and safety data.

31 Aug 2010

Phase 3 EINSTEIN-DVT clinical trial data can transform deep vein thrombosis treatment

Johnson & Johnson Pharmaceutical Research & Development, announced today that the investigational, oral anticoagulant rivaroxaban successfully demonstrated non-inferiority compared to the standard of care for the prevention of recurrent venous thromboembolism (VTE) in patients with acute symptomatic deep vein thrombosis (DVT), with a comparable safety profile.

31 Aug 2010

Boehringer Ingelheim announces sub-analysis result of RE-LY trial

Boehringer Ingelheim today announced results from a pre-specified, retrospective, un-blinded sub-analysis of the RE-LY trial the largest atrial fibrillation outcomes trial ever conducted were published in The Lancet.

30 Aug 2010

Lack of awareness among referring physicians limits intervention in venous system: MRG

Millennium Research Group (MRG), the global authority on medical technology market intelligence, finds that although venous procedures are set to grow by more than 10% through 2013, a lack of awareness among referring physicians is a major roadblock in increased interventions in the venous system.

26 Aug 2010

Blood coagulation, antimicrobial defence processes are functionally coupled: Research

The adaptive immune system can recognize and respond specifically to particular infectious agents. But the first line of defence against pathogens is the so-called innate immune system. This system reacts to invaders by initiating unspecific inflammatory responses which attract various types of specialized cells such as neutrophils to the site of the incursion.

4 Aug 2010

IL releases new HemosIL HIT-Ab(PF4-H) assay

Instrumentation Laboratory (IL) today announced the release of the new HemosIL HIT-Ab(PF4-H) assay as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. Delivering results in minutes, the HemosIL HIT-Ab(PF4-H) assay detects total immunoglobulin against Platelet Factor 4-Heparin complexes, the antibodies associated with the pathology of HIT.

4 Aug 2010

First generic version of Lovenox receives FDA approval for DVT

The U.S. Food and Drug Administration today approved the first generic version of Lovenox (enoxaparin sodium injection), an anti-coagulant drug used to prevent deep vein thrombosis, a potentially deadly blood clotting condition.

23 Jul 2010

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Bristol-Myers Squibb Company today reported results for the second quarter of 2010 which featured data on key marketed and investigational compounds in its oncology, diabetes and cardiovascular franchises, and growth in sales and EPS. The company also confirmed guidance for 2010 and minimum guidance for non-GAAP EPS in 2013.

22 Jul 2010